Recent 8-K filings for IDXG

• August 27, 2026, 8:30 AM ET other material materiality 0.60 neutral item 5.03item 7.01item 9.01

  Interpace Biosciences announces 1-for-5 reverse stock split to support Nasdaq uplisting

  1-for-5 reverse stock split effective 12:01 a.m. ET Aug 27, 2026; shares reduced from ~27.7M to ~5.5M.

• August 12, 2026, 4:15 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Interpace Q2 2026: revenue $9.1M, income $0.3M vs prior loss; thyroid revenue +9% YoY

  Q2 revenue $9.1M, up 9% Pro Forma (ex-PancraGEN); income from continuing ops $0.3M vs $0.5M loss prior year.

• May 14, 2026, 4:15 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Interpace Biosciences Q1 2026 revenue $9.0M, thyroid revenue up 12% YoY; reaffirms 16% growth guidance

  Q1 revenue $9.0M; GAAP down 22% YoY due to PancraGEN exit, but Pro Forma revenue up 14% to $9.0M from $7.9M.

• April 1, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Interpace Q4 revenue $9.2M, thyroid revenue +14% YoY; debt fully paid off

  Q4 revenue $9.2M, FY revenue $38.7M; Q4 income from cont. ops $22.8M (includes one-time tax adjustment).

• January 20, 2026, 6:59 PM ET other material materiality 0.85 positive item 2.02item 7.01item 9.01

  Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Guidance, and Preferred Stock Conversion

  Preliminary 2025 thyroid testing revenue of ~$34-35M, up 21% over prior year.

• December 3, 2025, 6:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Interpace Biosciences fully repays BroadOak term loan early, strengthens balance sheet

  Fully repaid outstanding term loan facility with BroadOak Capital Partners prior to maturity.

• November 12, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Interpace Biosciences Reports Q3 2025 Revenue of $8.8M, Thyroid Test Volume Up 12% YoY

  Q3 2025 revenue $8.8M, up 22% pro forma vs prior year; operating income $1.1M

• August 8, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Interpace Biosciences Q2 revenue down 23% to $9.2M; loss from continuing ops $0.5M

  Net revenue $9.2M (-23% YoY); loss from continuing ops $0.5M vs income $2.5M a year ago.

• May 8, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Interpace Q1 revenue $11.5M (+13% YoY); guides FY2025 ~$38M

  Net revenue $11.5M (+13% YoY); income from continuing ops $1.8M vs $0.8M.

• May 1, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 2.05item 8.01item 9.01 ◈ Restructurings & Charges

  Interpace Biosciences restructures after Medicare LCD ends PancraGEN coverage

  Medicare LCD L39365 ends PancraGEN reimbursement as of April 24, 2025; no specimens after May 2.

• March 6, 2025, 6:59 PM ET other material materiality 0.85 negative item 4.02 ◈ Auditor Changes

  Interpace Biosciences to restate 2023 and quarterly 2023/2024 financials due to accrued royalty errors

  Accrued royalties overstated by $5.3M to $7.1M across 2023 and 2024 quarterly balance sheets.

• January 27, 2025, 6:59 PM ET regulatory materiality 0.90 positive item 2.05item 8.01item 9.01

  Interpace Biosciences: CMS delays Genetic Testing LCD to April 24, 2025; Company re-evaluates restructuring plan

  CMS directed Medicare contractors to delay implementation of LCD L39365 from Feb 23 to April 24, 2025.

• January 21, 2025, 6:59 PM ET other material materiality 0.85 negative item 1.01item 2.03item 2.05 ◈ Restructurings & Charges

  Interpace restructures debt and cuts workforce after CMS drops PancraGEN coverage

  Fourth Amendment: monthly $500k principal payments Feb-Jun 2025, interest-only Jul-Dec, final balance due Dec 31, 2025; 1% restructuring fee paid on Jan 17, 2025.

• January 10, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 8.01item 9.01

  CMS final LCD denies coverage for Interpace's PancraGEN test; company to discontinue after Feb 7, 2025

  CMS issued final LCD L39365 establishing non-coverage for PancraGEN, a DNA-based test assessing pancreatic cyst cancer risk.

• November 6, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Interpace Biosciences Q3 revenue $12.3M, record test volume, swings to profit

  Q3 net revenue $12.3M, up 35% YoY ($9.1M); test volume up 26% to record levels.

• October 15, 2024, 7:59 PM ET other material materiality 0.65 positive item 1.01item 3.02item 3.03item 5.03item 7.01item 9.01

  Interpace exchanges all Series B Preferred for Series C Preferred; first step toward Nasdaq uplisting

  All 47,000 Series B Preferred shares (28,000 Ampersand, 19,000 1315 Capital) exchanged for Series C at $1,000 stated value.

• August 2, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Interpace Q2 revenue $12.0M (+9% YoY); operating income $2.2M vs $0.8M

  Test volume up 12% YoY to record levels; sixteenth consecutive quarter of YoY volume growth.

• May 9, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Interpace Q1 revenue $10.3M (+4% YoY); income from ops $0.6M; record test volume +10%

  Q1 net revenue $10.3M, up 4% YoY from $9.8M; test volume up 10% to record levels.

• March 13, 2024, 7:59 PM ET earnings materiality 0.78 positive item 2.02item 9.01 ◈ Earnings Releases

  Interpace Biosciences reports record FY2023 revenue $40.2M (+26% YoY), swings to profit of $1.1M.

  Q4 revenue $10.3M (+23% YoY); Q4 income from cont. ops $0.8M vs loss of $1.4M in prior year.

• December 12, 2023, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

  Director Robert Gorman resigns from Interpace board, cites compensation dispute

  Robert Gorman resigned as director and Chairman effective December 7, 2023.

• November 8, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Interpace Biosciences Q3 revenue $9.1M (+11% YoY); expects FY2023 revenue >$40M

  Q3 net revenue $9.1M, up 11% from $8.2M; test volume up 11% YoY.

• October 27, 2023, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings◈ Material Agreements

  Interpace Biosciences amends BroadOak loan: $2.5M lump sum to satisfy $3M terminal payment, rate cut to 8%

  Lump sum payment of $2.5M due by Oct 31, 2023 in full satisfaction of $3M terminal payment under the Loan and Security Agreement.

• August 9, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Interpace Q2 revenue $11.0M (+49% YoY); net income $0.4M vs loss

  Q2 net revenue $11.0M, up 49% YoY; gross margin improved to 62% from 52%.

• May 12, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Interpace Biosciences Q1 2023 revenue $9.8M, up 24% YoY; turns profitable

  Net revenue $9.8M (+24% YoY); test volume up ~20% to record levels.

• April 25, 2023, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

  Interpace Biosciences appoints Christopher McCarthy as Principal Financial Officer

  Christopher McCarthy, 31, appointed Principal Financial Officer effective April 21, 2023.

• March 27, 2023, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Interpace Biosciences Q4 revenue $8.3M (-9% YoY); FY revenue $31.8M (-4%); loss narrows

  Q4 net revenue $8.3M, down 9% from $9.1M; operating income $0.1M vs loss of $1.4M prior year.

• November 15, 2022, 6:59 PM ET other material materiality 0.60 neutral item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×5

  Interpace stockholders approve equity plan share increases and reverse split authorization

  Stockholders approved amendment to 2019 Equity Incentive Plan, increasing authorized shares by 1,000,000 to total 2,230,000.

• November 14, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Interpace Q3 revenue $8.2M (+2%), adjusted EBITDA positive; going concern removed

  Q3 revenue $8.2M, up 2% YoY; gross margin improved to 58% from 55%.

• October 4, 2022, 7:59 PM ET leadership materiality 0.60 negative item 5.02item 9.01 ◈ executive_change

  Interpace Biosciences CFO Thomas Freeburg resigns; continues as consultant and principal financial officer

  CFO Thomas Freeburg resigned effective Sept 30, 2022; will serve as consultant and acting principal financial officer until new CFO hired.

• September 7, 2022, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 2.01item 7.01item 9.01

  Interpace sells Pharma Services unit to Flagship for $7M; expects ~$5M annual cash flow improvement

  Sold Pharma Solutions business to Flagship Biosciences for ~$7M cash at close (plus up to $2M earnout based on revenue).

• August 15, 2022, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Interpace Q2 revenue $9.4M (-16% YoY), net loss $3.9M on ThyGeNEXT price cut

  Q2 net revenue $9.4M, down 16% YoY; net loss $3.9M vs $3.4M prior year.

• May 16, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Interpace Q1 revenue up 6% to $10.4M; net loss narrows to $2.2M from $4.2M

  Q1 revenue $10.4M, +6% YoY; net loss improved to $2.2M from $4.2M in Q1 2021.

• May 10, 2022, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 2.03item 9.01

  Interpace Biosciences issues $2M convertible note to BroadOak; conversion tied to PIPE of >=$10M

  $2M principal, 9% annual interest, unsecured, interest-only until Aug 5, 2022 maturity date.

• April 14, 2022, 7:59 PM ET other material materiality 0.60 neutral item 4.01item 9.01

  Interpace Biosciences dismisses BDO, hires EisnerAmper as auditor

  Terminated BDO USA, LLP as independent auditor effective April 13, 2022.

• March 31, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Interpace 2021 rev $41.3M (+28%), net loss improves to -$14.9M; CMS reversal on thyroid tests

  Full year 2021 net revenue $41.3M, up 28% YoY; Q4 revenue $10.9M, up 13% YoY.

• January 31, 2022, 6:59 PM ET regulatory materiality 0.80 negative item 1.02item 8.01item 9.01

  Interpace terminates rights offering due to adverse CMS policy change for thyroid tests

  Terminated rights offering and standby purchase agreement with 3K Limited Partnership effective January 28, 2022.

• November 10, 2021, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Interpace Q3 revenue $9.5M, net loss $3.6M; new $7.5M facility, $8M term loan, $30M rights offering

  Q3 revenue $9.5M (+15% YoY); loss from continuing ops $(3.5)M vs $(6.2)M; adjusted EBITDA $(1.8)M vs $(2.9)M.

• November 3, 2021, 7:59 PM ET debt materiality 0.65 positive item 1.01item 2.03item 8.01item 9.01

  Interpace enters $8M term loan with BroadOak at 9% to repay private equity loans

  $8M term loan from BroadOak at 9% interest, matures Oct 2024 or change-of-control.

• August 10, 2021, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Interpace Q2 revenue $11.2M (+105% YoY); gross margin 48% vs 29%, adj EBITDA loss narrows to $0.3M

  Net revenue $11.2M (+105% vs Q2 2020); six-month revenue $21.0M (+45% YoY).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

20 positive 9 negative 21 neutral

source · IDXG on sec.gov